Tags : M2GEN

Biotech

Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer

Shots: The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s oncology efforts The data will be accessed through M2GEN’s ORIEN which is a network of 18 cancer centers across the US The collaboration provides utility […]Read More